BioChaperone Lispro confirme son potentiel - ACHAT - OC 88€
ADOCIA en partenariat avec Lilly annonce aujourd’hui les résultats de la seconde étude évaluant BioChaperone Lispro, son insuline ultra rapide, à Humalog de Lilly. Les résultats préliminaires confirment ce que nous pouvions entrevoir après la première étude, c’est-à dire, un meilleur contrôle de la glycémie post prandiale chez des patients atteints d’un diabète de type 1 sur les deux premières heures. Deux autres points nous semblent importants à souligner: le nombre d’hypoglycémies entre les deux composés était identique et aucune réaction au site d’injection n’a été recensée. Cette étude confirme ainsi, selon nous, tout l’intérêt que porte Lilly sur le composé de la biotech francaise. Nous maintenons notre recommandation à ACHAT sans modifier à ce stade notre objectif de cours de 88€ (+40%).ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.